Novigenix | WebDisclosure

Switch to English

9472	Sociétés
185370	Mots-clés
117721	Articles
99262	Communiqués

Accueil
Sociétés
Novigenix

COMMUNIQUÉ DE PRESSE

publié le 17/01/2024 à 08:00, il y a 1 année 10 mois

Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling
Novigenix, a leader in AI healthcare solutions, is launching LITOSeek™, a revolutionary innovation that utilizes advanced AI and RNA analysis to reshape cancer care and expedite drug development. Leveraging precision immunology, Novigenix is set to empower biopharma companies and transform cancer treatment paradigms, offering a breakthrough in personalized cancer treatment. With a team of over 20 Ph.D.-level scientists dedicated to advancing next-generation liquid biopsy solutions, Novigenix is at the forefront of pioneering precision immunology for superior patient outcomes.

Novigenix LITOSeek AI Healthcare Solutions Precision Immunology Cancer Care

Les Echos

Publié le 04/12/2025 à 18:14, il y a 13 heures 40 minutes

Résiliation d'une convention conclue entre actionnaires
Publié le 04/12/2025 à 18:00, il y a 13 heures 55 minutes

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Publié le 04/12/2025 à 18:00, il y a 13 heures 55 minutes

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Publié le 04/12/2025 à 17:45, il y a 14 heures 10 minutes

Informations relatives au nombre total de droits de vote et d’actions
Publié le 04/12/2025 à 17:45, il y a 14 heures 10 minutes

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 05/12/2025 à 02:35, il y a 5 heures 20 minutes

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Publié le 05/12/2025 à 02:30, il y a 5 heures 25 minutes

Klondike Gold Announces AGM Results
Publié le 05/12/2025 à 01:00, il y a 6 heures 55 minutes

BEACN Closes First Tranche of Non-Brokered Private Placement
Publié le 04/12/2025 à 23:05, il y a 8 heures 50 minutes

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Publié le 04/12/2025 à 23:00, il y a 8 heures 55 minutes

NXT Energy Solutions Completes Data Acquisition for SFD Survey

Voir tout ACCESSWIRE

EQS Group

Publié le 05/12/2025 à 07:00, il y a 55 minutes

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Publié le 05/12/2025 à 03:30, il y a 4 heures 25 minutes

CGTN: What makes cooperation between China and France a two-way success
Publié le 04/12/2025 à 23:50, il y a 8 heures 4 minutes

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Publié le 04/12/2025 à 20:25, il y a 11 heures 30 minutes

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Publié le 04/12/2025 à 20:15, il y a 11 heures 40 minutes

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025